

1 Association of pitavastatin use with bone markers and bone mineral  
2 density in postmenopausal women

3 Jihye Hyun, Minji Sohn, Hyeran Oh, Soo Lim

4  
5 Department of Internal Medicine, Seoul National University College of Medicine and Seoul  
6 National University Bundang Hospital, Seongnam, South Korea

7  
8  
9 \* Corresponding author: Soo Lim, MD, PhD

10 Department of Internal Medicine, Seoul National University College of Medicine and Seoul

11 National University Bundang Hospital

12 300, Gumi-dong, Bundang-gu, Seongnam, Korea (postal code: 463-707)

13 E-mail: [limsoo@snu.ac.kr](mailto:limsoo@snu.ac.kr) Tel: 82-31-787- 7035 / Fax: 82-31-787-4052

14

15 ● Short title: Pitavastatin and Bone Health in Postmenopausal Women

16 ● Number of Tables and figures: 4 tables and 2 figures (4 supplementary tables)

17 ● Word counts: 5,735 words

18 ● Trial registration: NCT06359353

19

20 **Abstract**

21 **BACKGROUND:** The study aimed to evaluate the effects of pitavastatin therapy on  
22 biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal  
23 women with osteopenia or osteoporosis and hypercholesterolemia.

24 **METHODS AND RESULTS:** This prospective observational study recruited 70  
25 postmenopausal Korean women who were administered pitavastatin. Changes in BMD at the  
26 femoral neck (FN), total hip (TH), and lumbar spines (LS), as well as laboratory values  
27 related to bone turnover markers and lipid profiles, including lipoprotein subfractions, were  
28 assessed over 12 months. BMD was further observed during regular clinic visits up to 4 years.  
29 A total of 67 patients completed 12 months of pitavastatin therapy. There were no significant  
30 changes in BMD ( $-0.001 \pm 0.026$  at FN,  $-0.005 \pm 0.032$  at TH, and  $0.002 \pm 0.037$  at LS; all  
31  $P_s > 0.05$ ). Bone markers did not change except for procollagen type 1 N-propeptide (P1NP),  
32 which slightly decreased ( $-4.0 \pm 10.3$ ,  $P < 0.05$ ). Low-density lipoprotein (LDL) cholesterol  
33 levels decreased by 36% to 39% from baseline, and the LDL subfraction score decreased  
34 from  $2.85 \pm 1.79$  to  $1.80 \pm 0.63$  ( $P < 0.001$ ). During the extended observation period, BMD at  
35 FN and TH decreased by 0.85% and 1.69% per year, respectively, while BMD at the LS was  
36 preserved.

37 **CONCLUSIONS:** In postmenopausal women with osteopenia or osteoporosis requiring  
38 lipid-lowering therapy, one year of pitavastatin maintained BMD and effectively controlled  
39 cholesterol levels. BMD changes during statin therapy were more favorable than the natural  
40 decline. These findings suggest pitavastatin can be safely used in menopausal women without  
41 compromising bone health.

42 **Keywords: Pitavastatin, BMD, osteoporosis, bone markers**

43

## 44 **Introduction**

45 Statins, primarily used to lower cholesterol levels and prevent cardiovascular diseases, have  
46 been investigated for their additional effects on bone health.<sup>1</sup> A statin was associated with a  
47 lower risk of fractures in the elderly from a UK national database,<sup>2</sup> while other studies  
48 reported conflicting results, showing no effect on fractures in postmenopausal women or even  
49 worsening bone mineral density (BMD) in type 2 diabetes.<sup>3,4</sup> These indicate that statins needs  
50 to be used cautiously and tailored to specific cases based on the type of statins. Given the  
51 growing prevalence of osteoporosis in aging populations who might also require statins, the  
52 relationship between statins and bone health needs further evidence.

53 Osteoporosis is a skeletal disorder characterized by weakened bone strength and is  
54 increasingly prevalent in rapidly aging societies.<sup>5</sup> Traditional risk factors for osteoporosis  
55 include aging, hormonal changes, inadequate dietary calcium and vitamin D, and some  
56 medications.<sup>6</sup> The major determinant of bone loss in women during middle age is  
57 menopause,<sup>7</sup> but concomitant long-term medication may affect their bone health.

58 A systematic review and meta-analysis of 33 clinical trials found that statin treatment  
59 was associated with increased BMD at the total hip (TH) and lumbar spines (LS), and  
60 improved the bone formation marker, such as osteocalcin, while having a neutral effect on  
61 BMD at the femoral neck (FN), bone-specific alkaline phosphatase, and C-terminal  
62 telopeptide (CTX).<sup>8</sup> Most of the findings were from observational studies, with limited  
63 randomized controlled trials showing a neutral effect on BMD.

64 Pitavastatin has moderate-intensity cholesterol-lowering effects<sup>9</sup> and a long duration of  
65 action, providing convenience to patients regardless of the time of administration.<sup>10</sup> With  
66 minimal metabolism through the cytochrome P450 enzymes, pitavastatin is primarily  
67 metabolized through UDP-glucuronosyltransferase enzymes and has reduced potential for  
68 drug interaction.<sup>10,11</sup> These characteristics might be beneficial for the elderly who might use

69 multiple medications from the aspect of drug-drug interaction.

70 In this study, we aimed to investigate the effects of pitavastatin therapy on bone health in  
71 postmenopausal women with osteopenia or osteoporosis and concurrent hypercholesterolemia.  
72 We expected to provide valuable insights into its potential effects on patients with osteopenia  
73 or osteoporosis and hypercholesterolemia.

74

## 75 **Patients and Methods**

### 76 **Data Availability Statement**

77 The datasets collected and investigated in this study are available from the corresponding  
78 author upon a reasonable request.

79

### 80 **Study Design and Setting**

81 This study was designed as a prospective, single-arm, open label study and was approved by  
82 an independent ethics committee/Institutional Review Board (B-1902-520-004). It was  
83 registered at clinicaltrials.gov (NCT06359353) and conducted at Seoul National University  
84 Bundang Hospital. All participants provided written informed consent prior to participating in  
85 the study.

86 Our study size of 70 participants was set based on a reference study<sup>12</sup> that reported a  
87 significant reduction in serum N-terminal telopeptide of type 1 collagen (NTX) from  $15.53 \pm$   
88  $4.2$  nM BCE/mM Cr to  $12.06 \pm 2.6$  nM BCE/mM Cr after three months of pitavastatin  
89 treatment. We targeted 66 participants, accounting for a 10% dropout rate. We included  
90 postmenopausal women aged 75 years or younger. Eligibility was confirmed through initial  
91 screenings and medical records review, focusing on patients who were diagnosed with

92 osteopenia or osteoporosis ( $-3.0 \leq \text{T-score} \leq -1.5$ ), initiating pitavastatin treatment for  
93 hypercholesterolemia for the first time, and presenting with baseline bone resorption markers  
94 ( $\text{CTX} \geq 0.300 \text{ ng/mL}$  or urinary  $\text{NTX} > 16.5 \text{ nM BCE/mM Cr}$ ).

95 Patients were excluded based on the following criteria: (1) history of statin use for more  
96 than one month within the three months prior to the study; (2) treatment with oral or  
97 injectable glucocorticoids for over one week in the same period; (3) current use of  
98 thiazolidinediones; (4) ongoing treatment for malignant tumors.

99 All participants received pitavastatin orally at a daily dosage of 4 mg for 52 weeks or  
100 more. While most patients maintained the dosage of 4 mg of pitavastatin once daily  
101 throughout the study period, the dosage was decreased to 2 mg daily at physician's discretion.

102

### 103 **Variables and Outcome Measurements**

104 The primary outcome was the change in BMD after 12 months of pitavastatin therapy.  
105 Secondary outcomes included the changes in osteocalcin, procollagen type 1 N-terminal  
106 propeptide (P1NP), CTX, and NTX after 6 and 12 months. Additionally, laboratory values  
107 related to patients' general status, including cholesterol levels, glycated haemoglobin  
108 (HbA1c), liver and kidney function, as well as those related to bone mineral metabolism such  
109 as 25-hydroxyl-vitamin D (25OH-vitamin D) and parathyroid hormone (PTH) levels, were  
110 assessed at 3, 6 and 12 months.

111 BMD was measured using dual-energy X-ray absorptiometry (DXA) with a QDR 4500  
112 device (Hologic, Waltham, MA, USA). We also used the T-score, which compares an  
113 individual's BMD with the mean value for young, normal women and expresses the  
114 differences as a standard deviation score.<sup>13</sup> Changes in BMD and T-scores from baseline to  
115 12 months post-treatment at the following sites: left hip (including FN, TH), and LS (L1, L2,

116 L3, L4, and the average from L1 to L4) were observed. BMD was further investigated as part  
117 of an extended protocol in year 2, and also collected if examined during regular clinic visits  
118 for up to 4 years.

119 Body composition including body weight, height, and body mass index (BMI), was  
120 measured by standard methods with the participants wearing light clothing.

121 Biochemical markers of bone metabolism were measured: Osteocalcin and P1NP levels  
122 using the Elecsys N-MID Osteocalcin and Total P1NP assays (Roche), respectively. Urine  
123 NTX and CTX levels were assessed via an NTX ELISA kit (Inverness Medical) and the  
124 Elecsys B-CrossLaps assay (Roche). Serum calcium, phosphorus, 25OH-vitamin D, and PTH  
125 were evaluated using colorimetry (Hitachi 747), HPLC (Variant II Turbo, Bio-Rad), and  
126 chemiluminescence (LIAISON; DiaSorin), respectively.

127 Plasma glucose and HbA1c were determined using the glucose oxidase method (Hitachi  
128 747) and HPLC (Variant II Turbo). Serum AST, ALT, creatinine, and eGFR were measured  
129 with the Architect Ci8200 (Abbott). Cholesterol profiles were analyzed with Hitachi's  
130 Clinical Chemistry Analyzer. Urinary albumin and creatinine were quantified by turbidimetry  
131 (502X, A&T) and the Jaffe method (Hitachi 7170).

132 Lipoprotein subfractions were also measured using the Quantimetrix LDL Lipoprint  
133 System (Quantimetrix Corporation, Redondo Beach, CA, USA) following the manufacturer's  
134 instructions.<sup>14</sup> This method used high-resolution polyacrylamide gel electrophoresis to  
135 separate and measure very low-density lipoprotein (VLDL), intermediate-density lipoprotein  
136 (IDL), and LDL subfractions. IDL was divided into large (C), medium (B), and small (A)  
137 subfractions. The LDL subfraction score was calculated using the weighted area under the  
138 curve (AUC) of LDLs.

139

## 140 **Statistical Analysis**

141 All patients in the study were enrolled in the analysis. Clinical characteristics are presented as  
142 means  $\pm$  standard deviation (SD). To compare baseline and post-treatment values across all  
143 successive pairs during the follow-up period for each patient, we used paired *t*-tests to  
144 analyze changes in clinical variables. The mean annual percent change in BMD was  
145 calculated by dividing the difference between the baseline BMD and follow-up measurements  
146 of BMD by the baseline BMD, then dividing by the study period (in years) and multiplying  
147 by 100. Additionally, we analyzed over 4 years (1,614 days) of observations to compare the  
148 fitted slope of BMD changes in our cohort with those reported in other long-term studies (4  
149 years or more) on postmenopausal women who had no history of treatments affecting bone  
150 health, aiming to compare with natural BMD changes. A *t*-test was conducted to compare our  
151 estimated slope, derived from a simple linear regression model, with the average slopes of the  
152 international and Korean cohorts. For data management, participants who did not take their  
153 prescribed diabetes medication during the study period were excluded from the glucose level  
154 analysis. Also, BMD and T-score values that were deemed inappropriate due to specific  
155 reasons such as pin fixation, cement injection, etc., were excluded from the analysis, to  
156 account for variations in personal examination.

157 All statistical analyses were conducted using R software, version 4.3.3 (R Foundation  
158 for Statistical Computing, Vienna, Austria). A *P*-value of  $< 0.05$  was considered statistically  
159 significant, indicating evidence of a meaningful difference.

160

## 161 **Results**

### 162 **Baseline Characteristics of Study Participants**

163 A total of 70 patients with an average age of  $65.3 \pm 5.3$  years were enrolled (**Table S1**). The  
164 most common underlying diseases were diabetes (31.4%), osteopenia (30%), and  
165 hypothyroidism (22.9%). The lipid profiles of the study group showed a total cholesterol

166 levels of  $229 \pm 35$  mg/dL, triglyceride levels of  $127 \pm 54$  mg/dL, and LDL-cholesterol levels  
167 of  $145 \pm 25$  mg/dL. The serum 25OH-vitamin D levels averaged  $26.2 \pm 10.1$  ng/mL.

168

### 169 **Changes in Lipid Profiles and Biochemical Parameters over 12 months**

170 *Tables 1* and *2* present the changes in lipid profiles and biochemical parameters in 67 patients  
171 who received 12 months of pitavastatin treatment. LDL-cholesterol levels decreased from  
172  $145.7 \pm 24.1$  mg/dL to  $89.1 \pm 20.2$  mg/dL at 6 months and to  $93.7 \pm 30.1$  mg/dL at 12 months,  
173 showing declines of 38.8% and 35.7%, respectively. Four people reduced their dosage from 4  
174 mg to 2 mg (*Table 1*). Remnant cholesterol, triglycerides, VLDL, IDL-C, IDL-B, IDL-A, and  
175 LDL particles (LDL Large 1 to LDL Small 5) also decreased during the 1-year observation ( $P$   
176  $< 0.001$  for all time points).

177 The 25OH-vitamin D and PTH levels increased from baseline to 12 months ( $P = 0.012$   
178 and  $P = 0.038$ , respectively) (*Table 1*), while calcium levels did not change over the 12  
179 months.

180

### 181 **BMD and T-score Changes with Bone Turnover Markers over 12 months**

182 BMD measurements at all sites—FN, TH, and LS—showed no significant changes over 12  
183 months (*Table 3*): a  $-0.16\%$  decrease in BMD at FN (absolute change:  $-0.001 \pm 0.026$ ), a  $-$   
184  $0.66\%$  decrease at TH (absolute change:  $-0.005 \pm 0.032$ ), and a  $0.26\%$  increase at LS  
185 (absolute change:  $0.002 \pm 0.037$ ). Similarly, T-scores also did not show significant changes at  
186 any site. Although T-scores at the LS showed slight increases with absolute changes ranging  
187 from 0.03 to 0.08, these changes were not statistically significant.

188 The time-dependent changes in bone turnover markers over a period of 6 and 12 months  
189 are shown in *Figure 1*. There was no significant change in osteocalcin and the bone



190 resorption markers, NTX and CTX, at the 6-month and 12-month marks (**Figure 1A, 1C** and  
191 **1D**). Conversely, a significant decrease in the bone formation marker P1NP was observed  
192 (**Figure 1B**, both  $P < 0.05$ ).

193

#### 194 **Extended Observations of the Participants**

195 At the additional follow-up, 63 patients were further evaluated at a median of 26 months  
196 (IQR 24.8-31.8). Laboratory values and BMD changes at the third visit are detailed in **Table**  
197 **S2** and **S3**. The decrease in lipid parameters, including total cholesterol, LDL-cholesterol, and  
198 triglycerides, was maintained continuously in the extended observation (all  $P$ s  $< 0.001$ ).  
199 However, HDL-cholesterol did not change significantly. Additionally, 25OH-vitamin D levels  
200 showed a significant increase from baseline to the 26-month follow-up ( $P < 0.001$ ).

201 In assessing changes in BMD and T-scores over an extended period, we observed  
202 significant decreases at the FN: absolute change in BMD was  $-0.011 \pm 0.032$  ( $-0.85\%/year$ ,  $P$   
203  $= 0.013$ ), and in the T-score was  $-0.12 \pm 0.36$  ( $-3.01\%/year$ ,  $P = 0.011$ ); and at the TH: the  
204 absolute change in BMD was  $-0.027 \pm 0.055$  ( $-1.69\%/year$ ,  $P < 0.001$ ), and in the T-score  
205 was  $-0.24 \pm 0.39$  ( $-10.03\%/year$ ,  $P < 0.001$ ). No statistically significant changes were noted  
206 at the LS.

207 Furthermore, we indirectly compared our extended data, which includes examination  
208 beyond the second visit year up to four years, with longitudinal studies conducted over 4  
209 years or more on postmenopausal women from five international and two Korean cohorts  
210 (**Table S4**). The estimated slope of our cohort, along with the average slopes of international  
211 (FN:  $-0.010$ , TH:  $-0.014$ , LS:  $-0.021$ ) and Korean (FN:  $-0.008$ , TH:  $-0.008$ , LS:  $-0.001$ )  
212 cohorts at each site, are presented in **Figure 2**. The slopes of the linear fitted unadjusted  
213 models for our cohort at the FN ( $\beta = -0.003$ , SE = 0.001,  $P = 0.025$ ), TH ( $\beta = -0.005$ , SE =  
214 0.002,  $P = 0.004$ ), and LS ( $\beta = 0.001$ , SE = 0.002,  $P = 0.862$ ) showed significant differences

215 from the average slopes of the international cohorts (all  $P$ s < 0.05). However, compared to  
216 the Korean cohorts, the fitted linear slopes for our cohort were not significantly different at  
217 the TH ( $P = 0.146$ ) and LS ( $P = 0.937$ ).

218

### 219 **Safety and Tolerability**

220 A total of 29 (41.4%) patients experienced adverse events, most of which were mild severity.  
221 The most frequent adverse events (AEs) were musculoskeletal disorders, affecting 13 (17.1%)  
222 of patients. All patients continued the medication, with two patients reducing the dosage due  
223 to mild myalgia. Eight patients reported gastrointestinal disorders, while three experienced  
224 urinary disorders. One spinal fracture was observed as a result of a fall on an icy road, and  
225 one serious adverse event, hospitalization due to cholangitis, was observed during the study  
226 period. Adverse events summarized by organ in the participants are shown in **Table 4**.

227

### 228 **Discussion**

229 In our study, postmenopausal women with osteopenia or osteoporosis treated with  
230 pitavastatin exhibited no significant changes in BMD at FN, TH, and LS sites during the first  
231 year. Additionally, pitavastatin therapy significantly reduced LDL-cholesterol levels and LDL  
232 subfraction scores, also benefiting cardiovascular risk. The reduction in small, LDL  
233 subfraction levels after pitavastatin therapy is a new finding in the current study.<sup>15</sup> Our  
234 findings suggest that pitavastatin is a favorable option for treating dyslipidemia and does not  
235 negatively affect BMD or worsen the severity of osteopenia or osteoporosis in  
236 postmenopausal women.

237 Long-term use of pitavastatin therapy was found to be safe in the context of BMD  
238 changes compared to the natural decline observed in postmenopausal women (**Table S4** and  
239 **Figure S1**).<sup>7,16,17</sup> After one year of pitavastatin treatment, the percentage changes in BMD

240 were  $-0.16\%/year$  at the FN,  $-0.66\%/year$  at the TH, and  $0.26\%/year$  at the LS. These  
241 changes were similar or less severe than natural declines reported in previous studies.<sup>16-19</sup> The  
242 Framingham Osteoporosis Study, which included postmenopausal women aged 67-95 years,  
243 showed declines in BMD of  $-0.87\%/year$  at the FN during a 4-year follow-up period.<sup>19</sup> A  
244 study in Denmark that investigated BMD changes over a 2-year interval in postmenopausal  
245 women aged 60-69 years without conditions affecting bone metabolism, revealed a BMD  
246 decrease of  $-0.40\%/2$  years in the TH and an increase of  $0.50\%/2$  years in the LS.<sup>18</sup> Two  
247 Korean prospective studies reported annual BMD changes of  $-0.67\%$  and  $-0.87\%$  at the FN,  
248  $-0.66\%$  and  $0.95\%$  at the TH, and  $-0.18\%$  and  $0.27\%$  at the LS sites, respectively, among  
249 elderly women without osteoporosis treatment.<sup>16</sup> Compared to these studies, our study  
250 showed a smaller decrease at the FN and TH in postmenopausal women with similar age  
251 ranges, suggesting pitavastatin may have a neutral or slightly positive effect on bone  
252 metabolism.

253 Preclinical investigations have shown that statins possess anabolic effects on bone by  
254 diminishing the synthesis of mevalonate and impairing protein prenylation, thereby  
255 stimulating bone morphogenetic protein-2.<sup>20</sup> However, clinical studies have shown varied  
256 effects depending on specific conditions. In a case-control study, in women under 70 years,  
257 statin use is associated with decreased osteoporosis rates, likely due to their osteogenic  
258 effects, such as promoting osteoblast differentiation and inhibiting osteoclast activation.<sup>21</sup>  
259 Conversely, in women aged 70 years and above, statin use was associated with higher  
260 osteoporosis rates, possibly due to the estrogen-lowering effects of statins, which increase  
261 bone resorption and reduce bone density.<sup>8,22</sup>

262 Most studies investigating the effects of statins on BMD had relatively short durations,  
263 such as one year. Twelve-month treatment of simvastatin 20 mg did not change BMD at the  
264 FN and LS in 32 postmenopausal subjects with an average age of 56.8 years and a BMI of

265  $29.3 \pm 4.5 \text{ kg/m}^2$ .<sup>23</sup> Similarly, in a study involving 318 postmenopausal participants with  
266 osteopenia, aged 40-75 years, who were randomly assigned to receive a once-daily dose of  
267 atorvastatin (10, 20, 40, or 80 mg) or a placebo, there were no significant changes in BMD at  
268 the FN and LS in any treatment group.<sup>24</sup> Thus, studies investigating the efficacy and safety of  
269 statins on bone health have been limited and varied in study design, making it difficult to  
270 draw definitive conclusion.

271 The studies investigating the effects of statins on bone formation and resorption markers  
272 have also been limited, yielding mixed results. Osteocalcin levels initially increased and then  
273 decreased, indicating the transient effects of statins on bone metabolism. One study reported  
274 that a four-week treatment with 20 mg of simvastatin increased osteocalcin levels,<sup>25</sup> but this  
275 positive effect was attenuated with longer treatment durations.<sup>23</sup> In contrast, our study did not  
276 observe any significant changes in osteocalcin levels.

277 Regarding P1NP, our study showed a significant decrease over 12 months. This finding  
278 aligns with a cohort study of 500 statin users (age  $67 \pm 10$  years, BMI  $29.7 \pm 4.1 \text{ kg/m}^2$ ).  
279 Among these users, 81 individuals on stable doses of statins (pravastatin, lovastatin,  
280 fluvastatin, simvastatin, or atorvastatin) for less than a year exhibited significantly lower  
281 P1NP levels compared to 1,931 non-users with similar age and BMI.<sup>26</sup>

282 In a recent randomized study with 24 postmenopausal women, a statistically significant  
283 decrease in NTX was observed in patients receiving rosuvastatin (5 to 10 mg) but not in those  
284 receiving atorvastatin 20 mg.<sup>27</sup> A meta-analysis with 5 studies reported that statin treatment  
285 decreased NTX levels ( $-1.14 \text{ nM BCE}$ , 95% CI:  $-1.21, -0.07$ ).<sup>28</sup> Experimental studies  
286 reported that statins treatment suppressed osteoclast formation through the  
287 osteoprotegerin/receptor activator of nuclear factor kappa-B (NFkB) ligand/receptor  
288 activator of NFkB.<sup>29,30</sup> Significantly, our study found no changes in NTX and CTX levels  
289 after one year of pitavastatin treatment, indicating that pitavastatin may not increase bone

290 resorption, potentially stabilizing the overall bone turnover rate in postmenopausal women.

291 In a randomized controlled trial, disparate effects of statins on 25OH-vitamin D levels  
292 were reported: over an 8-week treatment period, 10 mg of rosuvastatin increased these levels,  
293 whereas 80 mg of fluvastatin did not.<sup>31</sup> Despite both dosages having equivalent drug  
294 potencies, their effects on vitamin D levels differed, suggesting that the impact of statin  
295 therapy on vitamin D levels might be inconsistent. The underlying mechanism remains  
296 unclear but likely involves the metabolism of vitamin D by CYP3A4 and CYP3A5 enzymes  
297 in the liver and intestines—pathways heavily utilized by statins, which could indicate a  
298 possible positive influence on vitamin D levels.<sup>32</sup> Furthermore, in our study, 25OH-vitamin D  
299 levels increased significantly over two years. Among these participants, 24 patients (35.3%)  
300 regularly took vitamin D and calcium supplements, which remained unchanged during the  
301 study period. Although the exact mechanisms by which statins affect vitamin D metabolism  
302 are not fully determined,<sup>33</sup> this could contribute beneficially to statin's impact on bone health.  
303 Taken together, given the variety of factors such as statin type, dosage, treatment duration,  
304 and patient characteristics influencing the effects of statins on bone metabolism, well-  
305 designed and larger studies are essential to provide definitive results.

306 In our study, we observed a reduction in LDL-cholesterol levels by 36-39% following  
307 the administration of 4 mg of pitavastatin. Furthermore, it decreased non-HDL-cholesterol  
308 levels from  $167.4 \pm 28.2$  mg/dL at baseline to  $111.6 \pm 33.0$  mg/dL at the 12-month follow-up.  
309 Similarly, in the REAL-CAD study, daily administration of 4 mg of pitavastatin significantly  
310 reduced cardiovascular events in 13,054 Japanese patients with stable coronary artery disease  
311 (HR = 0.81, 95% CI 0.69-0.95).<sup>34</sup> A decreased LDL subfraction score due to pitavastatin  
312 treatment, as found in our current study, reinforces the effectiveness of reducing  
313 cardiovascular risks. An additional benefit of pitavastatin is its demonstrated lower risk of  
314 new-onset diabetes mellitus compared to atorvastatin or rosuvastatin.<sup>35,36</sup>

315 In the current study, a control group was not included. However, establishing a no-  
316 medication group could be challenging, as all women with hypercholesterolemia require  
317 lipid-lowering medication. Instead, we compared the BMD changes in our study to those  
318 observed in population from both Asian as well as Western cohorts with longitudinal  
319 observations.

320

## 321 **Conclusions**

322 Our study suggests that pitavastatin therapy can be an ideal option for treating dyslipidemia  
323 in postmenopausal women with osteopenia or osteoporosis, without adversely affecting bone  
324 health over a period of up to 4 years.

325

326 **Affiliations**

327 Department of Internal Medicine, Seoul National University College of Medicine, Seoul  
328 National University Bundang Hospital, Seongnam, South Korea (J.H., M.S., H.O., S.L.).

329 **Source of Funding**

330 This work was supported, in part, by grants from Seoul National University Bundang  
331 Hospital (B-1902-320-004) and JW Pharmaceutical (06-2019-0128).

332 **Disclosures**

333 None.

334 **Supplementary Material**

335 Tables S1-S2

336

## 337 **References**

- 338 1. Gonyeau MJ. Statins and osteoporosis: a clinical review. *Pharmacotherapy*. 2005;25:228-243.  
339 doi: 10.1592/phco.25.2.228.56954
- 340 2. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors  
341 and the risk of fractures. *JAMA*. 2000;283:3205-3210. doi: 10.1001/jama.283.24.3205
- 342 3. LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE,  
343 McNeeley SG, Passaro MD, et al. Statin use, clinical fracture, and bone density in  
344 postmenopausal women: results from the Women's Health Initiative Observational Study.  
345 *Ann Intern Med*. 2003;139:97-104. doi: 10.7326/0003-4819-139-2-200307150-00009
- 346 4. Wada Y, Nakamura Y, Koshiyama H. Lack of positive correlation between statin use and  
347 bone mineral density in Japanese subjects with type 2 diabetes. *Arch Intern Med*.  
348 2000;160:2865. doi: 10.1001/archinte.160.18.2865
- 349 5. Ahn SH, Park SM, Park SY, Yoo JI, Jung HS, Nho JH, Kim SH, Lee YK, Ha YC, Jang S, et al.  
350 Osteoporosis and Osteoporotic Fracture Fact Sheet in Korea. *J Bone Metab*. 2020;27:281-  
351 290. doi: 10.11005/jbm.2020.27.4.281
- 352 6. Sozen T, Ozisik L, Basaran NC. An overview and management of osteoporosis. *Eur J*  
353 *Rheumatol*. 2017;4:46-56. doi: 10.5152/eurjrheum.2016.048
- 354 7. Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, Lo JC,  
355 Johnston JM, Cauley JA, Danielson ME, et al. Bone mineral density changes during the  
356 menopause transition in a multiethnic cohort of women. *J Clin Endocrinol Metab*.  
357 2008;93:861-868. doi: 10.1210/jc.2007-1876
- 358 8. An T, Hao J, Sun S, Li R, Yang M, Cheng G, Zou M. Efficacy of statins for osteoporosis: a  
359 systematic review and meta-analysis. *Osteoporos Int*. 2017;28:47-57. doi: 10.1007/s00198-  
360 016-3844-8
- 361 9. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb  
362 CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA Guideline on the Primary  
363 Prevention of Cardiovascular Disease: Executive Summary: A Report of the American  
364 College of Cardiology/American Heart Association Task Force on Clinical Practice  
365 Guidelines. *J Am Coll Cardiol*. 2019;74:1376-1414. doi: 10.1016/j.jacc.2019.03.009
- 366 10. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. *Int J Clin Pract*. 2005;59:239-252. doi:  
367 10.1111/j.1742-1241.2005.00461.x
- 368 11. Fujino H, Yamada I, Shimada S, Yoneda M, Kojima J. Metabolic fate of pitavastatin, a new  
369 inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in  
370 lactonization. *Xenobiotica*. 2003;33:27-41. doi: 10.1080/0049825021000017957
- 371 12. Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K.  
372 Short-term effects of pitavastatin on biochemical markers of bone turnover in patients  
373 with hypercholesterolemia. *Intern Med*. 2007;46:1967-1973. doi:  
374 10.2169/internalmedicine.46.0419



- 375 13. Diab DL, Watts NB. Diagnosis and treatment of osteoporosis in older adults. *Endocrinol*  
376 *Metab Clin North Am.* 2013;42:305-317. doi: 10.1016/j.ecl.2013.02.007
- 377 14. Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, McConnell JP.  
378 Development of a rapid, quantitative method for LDL subfractionation with use of the  
379 Quantimetrix Lipoprint LDL System. *Clin Chem.* 2001;47:266-274.
- 380 15. Choi CU, Seo HS, Lee EM, Shin SY, Choi UJ, Na JO, Lim HE, Kim JW, Kim EJ, Rha SW, et al.  
381 Statins do not decrease small, dense low-density lipoprotein. *Tex Heart Inst J.* 2010;37:421-  
382 428.
- 383 16. Park SY, Kim JH, Choi HJ, Ku EJ, Hong AR, Lee JH, Shin CS, Cho NH. Longitudinal changes  
384 in bone mineral density and trabecular bone score in Korean adults: a community-based  
385 prospective study. *Arch Osteoporos.* 2020;15:100. doi: 10.1007/s11657-020-00731-6
- 386 17. Lim Y, Jo K, Ha HS, Yim HW, Yoon KH, Lee WC, Son HY, Baek KH, Kang MI. The prevalence  
387 of osteoporosis and the rate of bone loss in Korean adults: the Chungju metabolic disease  
388 cohort (CMC) study. *Osteoporos Int.* 2017;28:1453-1459. doi: 10.1007/s00198-016-3893-z
- 389 18. Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men  
390 and women: a longitudinal study. *Osteoporos Int.* 2002;13:105-112. doi:  
391 10.1007/s001980200001
- 392 19. Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PW, Kiel DP. Risk  
393 factors for longitudinal bone loss in elderly men and women: the Framingham  
394 Osteoporosis Study. *J Bone Miner Res.* 2000;15:710-720. doi: 10.1359/jbmr.2000.15.4.710
- 395 20. Zhang Y, Bradley AD, Wang D, Reinhardt RA. Statins, bone metabolism and treatment of  
396 bone catabolic diseases. *Pharmacol Res.* 2014;88:53-61. doi: 10.1016/j.phrs.2013.12.009
- 397 21. Kim SY, Yoo DM, Min C, Kim JH, Kwon MJ, Kim JH, Choi HG. Association between  
398 Osteoporosis and Previous Statin Use: A Nested Case-Control Study. *Int J Environ Res*  
399 *Public Health.* 2021;18. doi: 10.3390/ijerph182211902
- 400 22. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ,  
401 Miller SS, Mulloy AL, et al. Alendronate and estrogen effects in postmenopausal women  
402 with low bone mineral density. Alendronate/Estrogen Study Group. *J Clin Endocrinol*  
403 *Metab.* 2000;85:720-726. doi: 10.1210/jcem.85.2.6393
- 404 23. Tikiz C, Tikiz H, Taneli F, Gumuser G, Tuzun C. Effects of simvastatin on bone mineral  
405 density and remodeling parameters in postmenopausal osteopenic subjects: 1-year follow-  
406 up study. *Clin Rheumatol.* 2005;24:447-452. doi: 10.1007/s10067-004-1053-x
- 407 24. Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, McClung MR.  
408 Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-  
409 blind, placebo-controlled, dose-ranging trial. *J Clin Endocrinol Metab.* 2007;92:4671-4677.  
410 doi: 10.1210/jc.2006-1909
- 411 25. Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW. Simvastatin increases serum  
412 osteocalcin concentration in patients treated for hypercholesterolaemia. *J Clin Endocrinol*  
413 *Metab.* 2001;86:4556-4559. doi: 10.1210/jcem.86.9.8001
- 414 26. Hernandez JL, Olmos JM, Romana G, Martinez J, Castillo J, Yezerska I, Ramos C, Gonzalez-

- 415 Macias J. Bone turnover markers in statin users: a population-based analysis from the  
416 Camargo Cohort Study. *Maturitas*. 2013;75:67-73. doi: 10.1016/j.maturitas.2013.02.003
- 417 27. Braszak-Cymerman A, Walczak MK, Oduah MT, Ludziejewska A, Bryl W. Comparison of the  
418 pleiotropic effect of atorvastatin and rosuvastatin on postmenopausal changes in bone  
419 turnover: A randomized comparative study. *Medicine (Baltimore)*. 2024;103:e38122. doi:  
420 10.1097/MD.00000000000038122
- 421 28. Zhao H, Tang Y, Zhen Y, Qi C, Chen S. The effect of statins on bone turnover biomarkers: a  
422 systematic review and meta-analysis of randomized controlled trials. *Endocr J*.  
423 2023;70:473-480. doi: 10.1507/endocrj.EJ22-0512
- 424 29. Sun X, Wei B, Peng Z, Fu Q, Wang C, Zhen J, Sun J. Protective effects of Dipsacus asper  
425 polysaccharide on osteoporosis in vivo by regulating RANKL/RANK/OPG/VEGF and  
426 PI3K/Akt/eNOS pathway. *Int J Biol Macromol*. 2019;129:579-587. doi:  
427 10.1016/j.ijbiomac.2019.02.022
- 428 30. Elewa HF, El-Remessy AB, Somanath PR, Fagan SC. Diverse effects of statins on  
429 angiogenesis: new therapeutic avenues. *Pharmacotherapy*. 2010;30:169-176. doi:  
430 10.1592/phco.30.2.169
- 431 31. Ertugrul DT, Yavuz B, Cil H, Ata N, Akin KO, Kucukazman M, Yalcin AA, Dal K, Yavuz BB,  
432 Tatal E. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin  
433 treatment on the levels of 25 hydroxyvitamin D. *Cardiovasc Ther*. 2011;29:146-152. doi:  
434 10.1111/j.1755-5922.2010.00141.x
- 435 32. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T, Kalhorn TF, Watkins PB,  
436 Schuetz EG, Thummel KE. Intestinal and hepatic CYP3A4 catalyze hydroxylation of  
437 1 $\alpha$ ,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. *Mol*  
438 *Pharmacol*. 2006;69:56-65. doi: 10.1124/mol.105.017392
- 439 33. Mazidi M, Rezaie P, Vatanparast H, Kengne AP. Effect of statins on serum vitamin D  
440 concentrations: a systematic review and meta-analysis. *Eur J Clin Invest*. 2017;47:93-101.  
441 doi: 10.1111/eci.12698
- 442 34. Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I,  
443 Nakagawa Y, et al. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With  
444 Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. *Circulation*.  
445 2018;137:1997-2009. doi: 10.1161/CIRCULATIONAHA.117.032615
- 446 35. Choi JY, Choi CU, Hwang SY, Choi BG, Jang WY, Kim DY, Kim W, Park EJ, Lee S, Na JO, et al.  
447 Effect of Pitavastatin Compared with Atorvastatin and Rosuvastatin on New-Onset Diabetes  
448 Mellitus in Patients With Acute Myocardial Infarction. *Am J Cardiol*. 2018;122:922-928. doi:  
449 10.1016/j.amjcard.2018.06.017
- 450 36. Seo WW, Seo SI, Kim Y, Yoo JJ, Shin WG, Kim J, You SC, Park RW, Park YM, Kim KJ, et al.  
451 Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and  
452 rosuvastatin: a distributed network analysis of 10 real-world databases. *Cardiovasc*  
453 *Diabetol*. 2022;21:82. doi: 10.1186/s12933-022-01524-6



**Table 1. Patient characteristics over 12 months**

Variable	Baseline, n=67	6 months, n=67	12 months, n=67
Weight, kg	57.0 ± 6.7	57.6 ± 6.9*	57.0 ± 6.8
BMI, kg/m <sup>2</sup>	23.5 ± 2.7	23.7 ± 2.9	23.5 ± 2.8
HbA1c, %	5.9 ± 0.6	6.1 ± 0.7**	6.1 ± 0.7**
Fasting glucose, mg/dL	103 ± 17	112 ± 18**	112 ± 18**
BUN, mg/dL	16 ± 4	16 ± 4	16 ± 4
Creatinine, mg/dL	0.63 ± 0.12	0.65 ± 0.12*	0.66 ± 0.12*
eGFR, mL/min/1.73 m <sup>2</sup>	93.3 ± 10.8	91.2 ± 10.1*	90.3 ± 9.8**
Uric acid, mg/dL	4.9 ± 1.0	4.7 ± 1.0*	4.7 ± 1.1*
Total protein, g/dL	7.3 ± 0.4	7.3 ± 0.3	7.3 ± 0.5
Total bilirubin, mg/dL	0.72 ± 0.24	0.77 ± 0.25*	0.75 ± 0.24
ALP, IU/L	85 ± 21	79 ± 21**	77 ± 21**
AST, IU/L	26 ± 7	28 ± 8*	30 ± 13*
ALT, IU/L	23 ± 14	29 ± 14**	30 ± 19*
<i>Bone Health and Mineral Metabolism</i>			
Calcium, mg/dL	9.6 ± 0.3	9.6 ± 0.3	9.6 ± 0.3
Phosphorus, mg/dL	3.9 ± 0.4	3.9 ± 0.5	3.9 ± 0.4
25OH-vitamin D, ng/mL	26.1 ± 13.3	-	29.6 ± 9.5*
PTH, pg/mL	31.4 ± 17.3	-	34.3 ± 9.5*

Data are mean ± SD. Paired-T test was conducted. \**P* < .05, \*\**P* < .001 vs. baseline.

BMI, body mass index; HbA1c, glycosylated hemoglobin; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PTH, parathyroid hormone; SD, standard deviation.

**Table 2. Changes in lipid profiles over 12 months**

Variable	Baseline, n=67	6 months, n=67	12 months, n=67
Total cholesterol, mg/dL	231.4 ± 35.7	162.7 ± 28.1**	173.2 ± 38.0**
LDL-cholesterol, mg/dL	146.1 ± 24.0	88.7 ± 19.9**	94.0 ± 30.0**
HDL-cholesterol, mg/dL	64.0 ± 17.4	64.1 ± 16.0	61.6 ± 16.8*
Triglycerides, mg/dL	126.3 ± 54.2	104.5 ± 39.7**	109.2 ± 42.5*
Non HDL-cholesterol, mg/dL	167.4 ± 28.2	98.6 ± 21.4**	111.6 ± 33.0**
Remnant cholesterol, mg/dL	21.3 ± 7.2	9.9 ± 6.1**	17.6 ± 10.2*
<i>Subpopulation analysis</i>			
VLDL, mg/dL	31.7 ± 11.3	23.2 ± 7.1**	24.1 ± 8.0**
IDL-C, mg/dL	24.5 ± 6.4	15.9 ± 4.1**	16.4 ± 4.0**
IDL-B, mg/dL	13.5 ± 3.9	9.3 ± 2.8**	9.5 ± 3.2**
IDL-A, mg/dL	15.1 ± 4.6	11.6 ± 3.8**	12.4 ± 4.1**
LDL Large-1, mg/dL	39.2 ± 15.7	28.6 ± 7.7**	31.7 ± 10.4**
LDL Large-2, mg/dL	32.7 ± 12.4	19.6 ± 6.8**	23.5 ± 10.6**
LDL Small-3, mg/dL	14.0 ± 7.8	4.9 ± 4.0**	7.1 ± 7.6**
LDL Small-4, mg/dL	6.2 ± 6.2	1.0 ± 2.8**	1.4 ± 2.9**
LDL Small-5, mg/dL	2.1 ± 4.2	0.3 ± 2.1*	0.1 ± 0.5*
LDL Small-6, mg/dL	0.3 ± 1.3	0.0 ± 0.1*	0.0 ± 0.0
LDL Small-7, mg/dL	0.0 ± 0.3	0.0 ± 0.0	0.0 ± 0.0
LDL subfraction score	2.86 ± 1.78	1.79 ± 0.62**	1.79 ± 0.50**

Data are presented as mean ± standard deviation. Paired-T test was conducted. \* $P < .05$ , \*\* $P < .001$  vs. baseline.

LDL, low-density lipoprotein; HDL, high-density lipoprotein; VLDL, very low-density lipoprotein; IDL, intermediate-density lipoprotein.

**Table 3. Changes in BMD and T-score comparisons between baseline and 12 months**

Site of measurement	Baseline, n=67	12 months, n=67	Baseline vs. 12 months		
			Absolute change	Mean percent change/year (%)	<sup>a</sup> P-value
<i>BMD, g/cm<sup>2</sup></i>					
Femoral Neck	0.618 ± 0.057	0.617 ± 0.061	-0.001 ± 0.026	-0.16	0.797
Total Hip	0.759 ± 0.063	0.753 ± 0.067	-0.005 ± 0.032	-0.66	0.201
Lumbar Spine	0.784 ± 0.068	0.786 ± 0.063	0.002 ± 0.037	0.26	0.733
L1	0.733 ± 0.073	0.735 ± 0.075	0.001 ± 0.040	0.14	0.773
L2	0.767 ± 0.077	0.772 ± 0.074	0.006 ± 0.042	0.78	0.266
L3	0.801 ± 0.079	0.810 ± 0.075	0.009 ± 0.038	1.12	0.071
L4	0.825 ± 0.074	0.833 ± 0.067	0.008 ± 0.046	0.97	0.210
<i>T-score</i>					
Femoral Neck	-1.91 ± 0.63	-1.92 ± 0.68	-0.02 ± 0.29	-1.05	0.646
Total Hip	-1.16 ± 0.64	-1.22 ± 0.66	-0.05 ± 0.33	-4.31	0.194
Lumbar Spine	-1.77 ± 0.62	-1.75 ± 0.58	0.03 ± 0.32	1.69	0.495
L1	-1.76 ± 0.64	-1.74 ± 0.67	0.03 ± 0.39	1.70	0.594
L2	-1.88 ± 0.69	-1.83 ± 0.66	0.05 ± 0.37	2.66	0.281
L3	-1.84 ± 0.71	-1.76 ± 0.67	0.07 ± 0.35	3.80	0.110
L4	-1.81 ± 0.67	-1.73 ± 0.59	0.08 ± 0.41	4.42	0.182

Data are mean ± standard deviation. <sup>a</sup>Paired-T test was conducted. P-values < .05 were considered significant.

BMD, bone mineral density.

**Table 4. Adverse events**

<b>Adverse events by organ</b>	<b>Patients, n=70</b>
Any adverse events - no. (%)	29 (41.4)
Musculoskeletal events - no. (%)	13 (18.5)
Back pain	2
Knee pain	2
Muscle pain	2
Myalgia	2
Ankle pain	1
Arthralgia	1
Chest pain	1
Cramp in leg	1
Shoulder pain	1
Spinal fracture	1
Tremor	1
Wrist pain	1
Gastrointestinal events - no. (%)	8 (11.4)
Dyspepsia	6
Abdominal pain	3
Anorexia	1
Enteritis	1
Epigastric pain	1
Nausea	1
Urinary events - no. (%)	3 (4.3)
Bacteriuria	1
Flank pain	1
Irregular bleeding	1
Other abnormalities- no. (%)	13 (18.5)
Edema	4

Adverse events of different organs were counted independently.


## Figure legends

**Figure 1. Changes in bone markers at baseline, 6 months, and 12 months.** (A) Osteocalcin, (B) P1NP, (C) NTX, and (D) CTX. Data are presented as mean  $\pm$  SD. A paired-T test indicated a significant difference between the two time points ( $P < 0.05$ ), as marked by an asterisk \*. P1NP, procollagen type 1 N-propeptide; NTX, N-terminal telopeptide; CTX, C-terminal telopeptide; SD, standard deviation.


**Figure 2. Slope of BMD changes comparing the current cohort using pitavastatin to International and Korean cohorts describing natural decline in menopausal women.** (A) Femoral Neck, (B) Total Hip, (C) Lumbar Spine. The figure illustrates the BMD difference ( $\text{g}/\text{cm}^2$ ) over time (years) for the current cohort (red line), with a red shaded area representing the confidence intervals of the linear fitted model. Participants in this study were observed for up to 4 years (1,614 days), including an examination beyond the second year, by visiting the regular clinic annually. An asterisk \* indicates a significant difference between the estimated slope of the current cohort and the averaged reference slopes, represented by solid lines, of the international and Korean cohorts ( $P < 0.05$ ). The individual reference cohort slopes of the international and Korean cohorts, as described in **Table S4**, are shown as dotted lines in blue and black, respectively. The range of slopes for both international and Korean cohorts is represented as a gray shaded area.




### A. Osteocalcin




### B. P1NP




### C. NTX




### D. CTX



### A. Femoral Neck



### B. Total Hip



### C. Lumbar Spine

